# Corteva Agriscience account plan

> Corteva is an Indianapolis crop protection company (NYSE: CTVA); its crop protection segment had $7,503 million of 2025 net sales before the seed spin-off.

## At a glance

Corteva, Inc. (NYSE: CTVA), headquartered in Indianapolis, Indiana, became a pure crop protection company on October 1, 2026, when it spun off its Seed business as Vylor Inc. It sells herbicides, insecticides, fungicides, biologicals, nitrogen stabilizers and seed-applied technologies to growers in approximately 110 countries, competing with BASF, Bayer, FMC, Syngenta and ChemChina and with generic producers. Before the split, the combined company had FY2025 net sales of $17,401 million, income from continuing operations of $1,204 million, operating EBITDA of $3,848 million and approximately 21,500 employees at December 31, 2025. The Crop Protection segment, the scope of today's Corteva, had 2025 net sales of $7,503 million and segment operating EBITDA of $1,350 million. Luke Kissam is CEO.

## Business units

- **Crop Protection (today's Corteva)** ($7,503 million 2025 net sales, about 43 percent of pre-spin group net sales): Herbicides ($3,730 million in 2025), insecticides ($1,669 million), fungicides ($1,140 million), biologicals ($519 million) and nitrogen management, under brands such as Arylex, Enlist One, Pyraxalt, Isoclast, Zorvec, Instinct, N-Serve and Utrisha. 2025 net sales rose 2 percent on 5 percent volume growth, with price down 2 percent mainly in Latin America. North America was the largest region at $2,753 million, followed by Latin America at $2,314 million.
- **Seed (spun off as Vylor Inc.)** ($9,898 million 2025 net sales, about 57 percent of pre-spin group net sales): Corn, soybean and other seed under Pioneer, Brevant and regional brands, with traits such as Enlist E3 and PowerCore. It grew 4 percent in 2025 with segment operating EBITDA of $2,636 million, and became the separate company Vylor Inc. on October 1, 2026.

## Strategic priorities

- **Innovation-led growth**: The standalone company rests growth on its R&D pipeline, put at $11 billion, and plans 12 new products over the next decade, including five biologicals with potential of approximately $4 billion of peak revenue. Seven active chemicals launched over the last decade are expected to generate $1.4 billion in 2026.
- **Defending molecules against generics**: Corteva extends the value of active ingredients through new formulations, mixtures and blends with biologicals, and says development must get faster and cheaper; Kissam said nothing major comes off patent by the end of 2028.
- **Market-specific go-to-market in Brazil**: Brazil's crop protection market is sized at $14 billion, where Corteva generates roughly $1.7 billion; it sells directly in the north and through Emblema regional distributors and the Escalas cooperative program in the south, and is re-examining direct sales, co-ops and distribution.
- **Cost structure overhaul**: A third party is reviewing processes, manufacturing footprint, logistics, country and product exits, routes to market and back office, with technology and AI layered on over "the next 4 to 6 to 8 quarters"; a hiring freeze and tighter SG&A are in place.
- **Balance sheet and capital returns**: The CFO targets about $1.5 billion of year-end cash, about $1 billion of financial debt and capex around $200 million a year; the Board authorized the first dividend after the spin, and buybacks are expected in 2027.
- **Partnerships and licensing**: Kissam said Corteva is "open for business" for licensing and partnerships with universities, start-ups and competitors, citing the FMC rimisoxafen deal.

## Latest results

In the third quarter of 2026, its first as a standalone crop protection company, Corteva's net sales fell 9 percent to $1,591 million from $1,742 million, with price down 7 percent and volume down 2 percent; adjusted pro forma operating EBITDA was $222 million against $268 million. Latin America fell to $570 million from $791 million on elevated channel inventory and farmer liquidity constraints in Brazil, while North America rose 7 percent, EMEA 12 percent and Asia Pacific 3 percent. New product volumes grew 20 percent. Year to date, net sales were $5,357 million (-1 percent) and adjusted pro forma operating EBITDA was flat at $943 million with a 17.6 percent margin. Full-year 2026 guidance was cut to adjusted pro forma operating EBITDA of $1.1 billion to $1.125 billion and operating EPS of $0.76 to $0.80, a cut the CFO called "100% Brazil driven".

## Investments and deals

- **Seed spin-off**: Seed was separated as Vylor Inc. on October 1, 2026; separation costs were $230 million in the first nine months of 2026, and Corteva's revolving credit facility was reduced to $2.0 billion and extended to August 2031.
- **Crop Protection network restructuring**: The Operations Strategy Restructuring Program exits production at Pittsburg, California, and in June 2026 moved to a next phase including the intended cessation of production in Asturias, Spain; a further network optimization is expected to be substantially complete in 2028, with approximately $130 million to $140 million of net pre-tax charges in 2026.
- **2026 workforce restructuring**: Approved March 15, 2026: workforce reductions across commercial and support functions, $70 million to $80 million of severance and an estimated $115 million to $125 million of run-rate savings by 2027.
- **Bayer resolution**: In January 2026 Corteva paid $610 million to settle its disputes with Bayer, ending all litigation between the parties and terminating disputed royalty obligations.

## Challenges and risks

- **Brazil downturn and channel inventory**: Kissam said "too much of the product we sold into the Brazil channel last year didn't go to ground", with roughly $250 million of extra revenue in the channel; the Brazilian sellout market is down roughly 12 percent year to date.
- **Generic and acetochlor price pressure**: Price was a roughly $120 million headwind in the third quarter of 2026, about 90 percent from US acetochlor and generic pressure in Brazil; 80 percent of full-year pricing pressure comes from acetochlor and five molecules in Brazil.
- **Inherited cost base**: Kissam said "we simply cannot afford the infrastructure we inherited", and some R&D projects are being paused for a year.
- **Regulatory complexity**: Products are registered country by country, EPA reviews under the Endangered Species Act can add use restrictions, and the 10-K says approval processes "are becoming increasingly more complex".
- **Legacy PFAS liabilities**: PFAS liabilities are shared with Chemours and DuPont under a 2021 memorandum of understanding, and state attorneys general opposed the spin-off over PFAS concerns.

## What leadership says

> "We executed well against the things we can control. New products performed strongly, productivity delivered, and we generated broad-based organic growth outside Latin America." — Luke Kissam, Chief Executive Officer, Third-quarter 2026 earnings release, 2026-11-11

> "Corteva has a balanced portfolio. We're not a one-trick pony." — Luke Kissam, Chief Executive Officer, Investor Day coverage, AgNavigator, 2026-09-15

> "North and South Brazil are fundamentally different markets, so we don't treat them the same" — Brook Cunningham, Chief Commercial Officer, Investor Day coverage, AgNavigator, 2026-09-15

> "we simply cannot afford the infrastructure we inherited." — Luke Kissam, Chief Executive Officer, Q3 2026 earnings call, 2026-11-12


## Where a supplier can help

- **Cost and footprint transformation**: Tied to the cost structure overhaul: consulting, process simplification, logistics and AI tooling for the review of footprint, routes to market and back office over the coming quarters.
- **Faster, cheaper development**: Tied to the generics defence and innovation priorities: formulation, R&D productivity and regulatory data services that shorten development of new mixtures and biologicals.
- **Brazil route-to-market and credit tools**: Tied to the Brazil challenge: channel inventory visibility, distributor credit risk and direct-sales tooling as Corteva re-examines how it sells in Brazil.
- **Standalone back office**: Tied to the seed spin-off: IT, finance and shared-service suppliers helping a newly separated company run without Vylor service arrangements.
- **Manufacturing network changes**: Tied to the restructuring of the crop protection network: contract manufacturing and formulation partners as sites such as Pittsburg and Asturias wind down.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Corteva, Inc. Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1755672/000175567226000004/ctva-20251231.htm)

Annual report · 2026-02-12

- FY2025 10-K of Corteva as it stood before the split: a seed and crop protection group headquartered in Indianapolis, selling in approximately 110 countries, with approximately 21,500 employees at December 31, 2025. On October 1, 2025 it announced the separation of Seed and Crop Protection into two public companies (completed October 1, 2026: Seed became Vylor Inc., Crop Protection kept the Corteva name).
- 2025 net sales $17,401 million (2024: $16,908 million), driven by a 1 percent increase in price and a 3 percent increase in volume; operating EBITDA (non-GAAP) $3,848 million (2024: $3,376 million); income from continuing operations after income taxes $1,204 million.
- Seed: net sales $9,898 million (+4 percent), segment operating EBITDA $2,636 million (+19 percent), margin up approximately 340 basis points; corn alone $7,002 million.
- Crop Protection (today's Corteva): net sales $7,503 million (+2 percent; volume +5 percent, price -2 percent), segment operating EBITDA $1,350 million (+6 percent); herbicides $3,730 million, insecticides $1,669 million, fungicides $1,140 million, biologicals $519 million.
- Geography: North America 52 percent of sales ($9,024 million), Latin America 22 percent ($3,928 million; Brazil $2,900 million), EMEA 18 percent, Asia Pacific 8 percent.
- Cash: operating cash flow $3,457 million, capex $591 million, free cash flow $2,866 million; approximately $1.5 billion returned to shareholders; 2026 capex expected at approximately $600 million.
- Bayer litigation settled as of January 2026: Corteva pays $610 million, drops its AAD-1 claims, and royalty obligations for Enlist E3 soybeans are terminated; there is no remaining litigation between the parties.
- Crop Protection Operations Strategy Restructuring Program (exit of Pittsburg, California production): $650-700 million of total pre-tax charges expected, targeting an estimated $180 million of run-rate savings by 2027.
- Main risks: regulatory approvals (including ESA reviews in the US), pipeline delivery, weather and climate, competition and generics, customer credit (customer financing), PFAS legacy liabilities shared with Chemours and DuPont, and execution of the separation.

### [Corteva Reports Third-Quarter 2026 Results; Updates FY 2026 Outlook (earnings release, first quarter as a standalone crop protection company)](https://www.sec.gov/Archives/edgar/data/1755672/000175567226000031/a3q_2026xearningsxnewsxr.htm)

Interim report · 2026-11-11

- First results release of Corteva as "a global crop protection company" after the October 1, 2026 spin-off of its Seed business as Vylor; figures are adjusted pro forma for the crop protection business.
- 3Q 2026 net sales $1.59B (-9 percent; organic -9 percent): volume -2 percent, price -7 percent; adjusted pro forma operating EBITDA $222 million, down 17 percent; pro forma GAAP loss from continuing operations $(54) million.
- Regions 3Q: North America $574 million (+7 percent; volume +19 percent), EMEA $239 million (+12 percent), Asia Pacific $208 million (+3 percent), Latin America $570 million (-28 percent; organic -31 percent, volumes -24 percent on Brazil channel inventory and farmer liquidity constraints).
- YTD 2026 net sales $5,357 million (-1 percent; organic -4 percent) and operating EBITDA $943 million (flat), margin up 30 basis points to 17.6 percent.
- Pricing pressure concentrated in US acetochlor and in molecules late in their lifecycle in Brazil.
- FY2026 guidance cut on Brazil: adjusted pro forma operating EBITDA $1.1 to $1.125 billion; operating EPS $0.76 to $0.80.
- Board authorized the first common dividend post spin; 2026 net pre-tax restructuring charges of approximately $130-140 million expected for the Crop Protection network optimisation, substantially complete in 2028.
- CEO Luke Kissam: "our strategy has not changed. Innovation, productivity and disciplined execution remain the foundation for sustainable long-term growth."

### [Corteva, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (last pre-separation period, Seed and Crop Protection combined)](https://www.sec.gov/Archives/edgar/data/1755672/000175567226000035/ctva-20260930.htm)

Interim report · 2026-11-12

- 10-Q for 3Q 2026, the last quarter before the October 1, 2026 separation; it still consolidates Seed and Crop Protection. For accounting, Vylor (Seed) is the successor to the historical Corteva, and the Crop Protection financial statements become Corteva's history going forward.
- 3Q 2026 net sales $2,458 million (-6 percent: volume -6 percent, price -2 percent, currency +2 percent); operating EBITDA $(68) million vs $49 million; loss from continuing operations $(527) million.
- Nine months 2026: net sales $13,742 million (+2 percent), operating EBITDA $3,631 million (vs $3,402 million), income from continuing operations $1,415 million.
- Crop Protection 3Q: net sales $1,553 million (-9 percent; price -7 percent, volume -2 percent), segment operating EBITDA $213 million (-24 percent). Nine months: $5,282 million (-1 percent), EBITDA $989 million (flat).
- Seed 3Q: $905 million (-1 percent), EBITDA $(246) million; nine months $8,460 million (+4 percent), EBITDA $2,754 million (+10 percent).
- 2026 Restructuring Actions (March 2026): $70-80 million of severance to right-size for standalone models, targeting $115-125 million of run-rate savings by 2027; next phase of the Crop Protection footprint plan includes intended cessation of production at Asturias, Spain.
- Debt rose to $7,446 million at September 30, 2026 (vs $2,580 million at end-2025) on separation financing, the Bayer payment, the FMC rimisoxafen prepayment and working capital; about $860 million returned to shareholders in nine months.

### [Corteva Q3 2026 earnings call - first call as a standalone crop protection company (transcript)](https://www.fool.com/earnings/call-transcripts/2026/11/12/corteva-inc-ctva-q3-2026-earnings-call-transcript/)

Executive talk · Luke Kissam, Chief Executive Officer · 2026-11-12

- First earnings call of Corteva as a standalone crop protection company, led by CEO Luke Kissam and CFO Jeff Rudolph.
- 3Q net sales $1.6 billion (-9 percent), operating EBITDA $222 million (-17 percent), margin 14 percent; new product volumes +20 percent with growth in every region.
- Brazil is the problem: Latin America organic sales -31 percent; Kissam says "too much of the product we sold into the Brazil channel last year didn't go to ground" and estimates roughly $250 million of excess revenue in the channel; sellout market down roughly 12 percent year to date.
- FY2026 operating EBITDA guide cut from about $1.3 billion (Investor Day) to $1.1-1.125 billion, "100% Brazil driven"; 80 percent of Brazil price headwinds come from 5 products.
- US acetochlor drove the North America price decline (about $60 million in 3Q, about $40 million expected in 4Q), tapering through 1Q-2Q 2027.
- Cost overhaul: hiring freeze, tighter SG&A, some R&D projects paused for a year, a third party reviewing the cost structure; "we simply cannot afford the infrastructure we inherited."
- Brazil under review: Kissam refuses to extend credit or push product elsewhere and is examining whether to go direct, through co-ops or distribution; "I'm not going to do anything if we can't make money."
- Capital: year-end cash target about $1.5 billion, about $1 billion of financial debt, capex run rate about $200 million; buybacks blocked in 4Q by spin tax representations but part of 2027 priorities; Kissam expects to grow in 2027.

### [Corteva Q4 2025 earnings call - 2026 guidance, Bayer resolution and separation timeline (transcript)](https://www.fool.com/earnings/call-transcripts/2026/05/06/corteva-ctva-q4-2025-earnings-transcript/)

Executive talk · Charles Magro, Chief Executive Officer · 2026-02-04

- Last full-year call of the combined Corteva (seed and crop protection), held February 4, 2026 by CEO Charles Magro and CFO David Johnson, with Seed head Judd O'Connor and Crop Protection head Robert King.
- 2025: operating EBITDA $3.85 billion, up 14 percent, margin over 22 percent (up about 215 basis points); free cash flow $2.9 billion; about $1.5 billion returned to shareholders.
- 2026 guidance: operating EBITDA $4.0-4.2 billion (about 7 percent growth at the midpoint), operating EPS $3.45-3.70; about 60 percent of sales and roughly 85 percent of EBITDA in the first half.
- Crop Protection: over $300 million of productivity and cost benefits in 2025; a $9 billion pipeline; about two-thirds of the portfolio differentiated; 2026 CP price expected down low single digits, volume up mid single digits.
- Tariffs about $80 million of 2026 cost, almost all crop protection actives imported from China into the US.
- Bayer resolution: $610 million payment, royalty neutrality in 2026 (2 years early), corn licensing as early as 2027, entry into US cotton licensing, about $1 billion of aggregate earnings upside over 10 years.
- Separation on track for the second half of 2026, "most likely sometime in the fourth quarter"; net dissynergies estimated at roughly $100 million, $50 million in the 2026 guide.

### [Corteva is 'not a one-trick pony,' C-suite outlines strategy to grow crop protection business post-spin (AgNavigator, Investor Day coverage)](https://www.agnavigator.com/Article/2026/09/15/corteva-outlines-post-spin-crop-protection-strategy-amid-attorneys-general-pushback/)

Executive talk · Luke Kissam, Chief Executive Officer · 2026-09-15

- Trade-press report (AgNavigator, September 15, 2026) on the New Corteva Investor Day, quoting CEO Luke Kissam, CTO Reza Rasoulpour and Chief Commercial Officer Brook Cunningham.
- Growth plan: R&D pipeline, go-to-market tailored by market, and extending the value of active ingredients through new formulations and mixtures.
- Seven new active ingredients launched over the last decade are expected to generate $1.4 billion in 2026 and approximately $2.5 billion at peak.
- 12 new products planned over the next decade, including five biologicals, with "the potential to create approximately $4 billion of peak revenue"; the pipeline is put at $11 billion.
- Kissam: "We're not a one-trick pony. We're not dependent on any one geography, one crop, one segment, or one active ingredient"
- Since 2020 Corteva has launched over 1,000 products, about 3,200 regulatory approvals and 3,800 patents; R&D runs on a microbial discovery platform, an AI-enabled development platform and a predictive safety platform.
- Brazil: a $14 billion addressable crop protection market ($8 billion north, $6 billion south) where Corteva makes roughly $1.7 billion; direct sales with barter or credit in the north, Emblema regional distributors and the Escalas cooperative program in the south.
- Spin-off faced opposition from a group of state attorneys general over PFAS liability concerns.

## Questions about Corteva Agriscience

### What does Corteva do?

Since October 1, 2026 Corteva is a pure crop protection company selling herbicides, insecticides, fungicides, biologicals and seed-applied technologies to growers in approximately 110 countries. Its former Seed business is now Vylor Inc.

### What is Corteva's revenue?

The Crop Protection business had 2025 net sales of $7,503 million; the pre-spin combined company reported $17,401 million. For 2026 Corteva guides adjusted pro forma operating EBITDA of $1.1 billion to $1.125 billion.

### How many employees does Corteva have?

The combined company employed approximately 21,500 people at December 31, 2025, before the seed spin-off; no post-spin figure is given.

### Who leads Corteva?

Luke Kissam is CEO and Jeff Rudolph is CFO of the standalone crop protection company.

### What is Corteva's strategy?

Growth through its R&D pipeline, new formulations and mixtures that extend active ingredients, and go-to-market tailored to each market, combined with a broad cost structure review.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
